Regeneron Pharmaceuticals, Inc. is an American biotechnology company headquartered in Westchester County, New York. The company was founded in 1988.
Company profile
Ticker
REGN
Exchange
Website
CEO
Leonard Schleifer
Employees
Incorporated
Location
Fiscal year end
Industry (SIC)
Former names
REGENERON PHARMACEUTICALS INC
SEC CIK
Corporate docs
Subsidiaries
Checkmate Pharmaceuticals, Inc. • Decibel Securities Corporation • Decibel Therapeutics Australia Pty Ltd • Decibel Therapeutics, Inc. • Eastside Campus Holdings LLC • Loop Road Holdings LLC • Old Saw Mill Holdings LLC • OSMR Holdings • Regeneron Assurance, Inc. • Regeneron Atlantic Holdings ...
IRS number
133444607
REGN stock data
Latest filings (excl ownership)
10-K
2023 FY
Annual report
5 Feb 24
8-K
Regeneron Reports Fourth Quarter and Full Year 2023 Financial and Operating Results
2 Feb 24
8-K
Departure of Directors or Certain Officers
31 Jan 24
8-K
2 Strategy & Business Update J.P.Morgan Healthcare Conference 2024 Co - Founder, Board Co - Chair, President & Chief Executive Officer
8 Jan 24
10-Q
2023 Q3
Quarterly report
2 Nov 23
8-K
Regeneron Reports Third Quarter 2023 Financial and Operating Results
2 Nov 23
8-K
Results of Operations and Financial Condition
5 Oct 23
SC TO-T/A
Third party tender offer statement (amended)
25 Sep 23
SC TO-T/A
Third party tender offer statement (amended)
12 Sep 23
8-K/A
Submission of Matters to a Vote of Security Holders
8 Sep 23
Transcripts
REGN
Earnings call transcript
2023 Q4
2 Feb 24
REGN
Earnings call transcript
2023 Q3
2 Nov 23
REGN
Earnings call transcript
2023 Q2
3 Aug 23
REGN
Earnings call transcript
2023 Q1
4 May 23
REGN
Earnings call transcript
2022 Q4
3 Feb 23
REGN
Earnings call transcript
2022 Q3
3 Nov 22
REGN
Earnings call transcript
2022 Q2
3 Aug 22
REGN
Earnings call transcript
2022 Q1
4 May 22
REGN
Earnings call transcript
2021 Q4
4 Feb 22
REGN
Earnings call transcript
2021 Q3
4 Nov 21
Latest ownership filings
4
ANDREW J MURPHY
15 Mar 24
144
Notice of proposed sale of securities
14 Mar 24
4
ARTHUR F RYAN
5 Mar 24
4
Marion McCourt
5 Mar 24
144
Notice of proposed sale of securities
1 Mar 24
4
JOSEPH J LAROSA
28 Feb 24
4
GEORGE L SING
28 Feb 24
4
NEIL STAHL
28 Feb 24
144
Notice of proposed sale of securities
26 Feb 24
4
Bonnie L Bassler
26 Feb 24
Financial summary
Quarter (USD) | Sep 23 | Jun 23 | Mar 23 | Dec 22 | |
---|---|---|---|---|---|
Revenue | |||||
Cost of revenue | |||||
Operating income | |||||
Operating margin | |||||
Net income | |||||
Net profit margin | |||||
Cash on hand | |||||
Change in cash | |||||
Diluted EPS |
Annual (USD) | Dec 22 | Dec 21 | Dec 20 | Dec 19 | |
---|---|---|---|---|---|
Revenue | |||||
Cost of revenue | |||||
Operating income | |||||
Operating margin | |||||
Net income | |||||
Net profit margin | |||||
Cash on hand | |||||
Change in cash | |||||
Diluted EPS |
Cash burn rate (est.) | Burn method: Change in cash | Burn method: Operating income | Burn method: FCF (opex + capex) | Last Q | Avg 4Q | Last Q | Avg 4Q | Last Q | Avg 4Q |
---|---|---|---|---|---|---|
Cash on hand (at last report) | 2.16 bn | 2.16 bn | 2.16 bn | 2.16 bn | 2.16 bn | 2.16 bn |
Cash burn (monthly) | (no burn) | 112.05 mm | (no burn) | (no burn) | (no burn) | (no burn) |
Cash used (since last report) | n/a | 670.79 mm | n/a | n/a | n/a | n/a |
Cash remaining | n/a | 1.49 bn | n/a | n/a | n/a | n/a |
Runway (months of cash) | n/a | 13.3 | n/a | n/a | n/a | n/a |
Institutional ownership, Q4 2023
65.3% owned by funds/institutions
13F holders | Current |
---|---|
Total holders | 1010 |
Opened positions | 132 |
Closed positions | 268 |
Increased positions | 351 |
Reduced positions | 358 |
13F shares | Current |
---|---|
Total value | 57.67 tn |
Total shares | 70.48 mm |
Total puts | 373.37 k |
Total calls | 264.44 k |
Total put/call ratio | 1.4 |
Largest owners | Shares | Value |
---|---|---|
FMR | 10.32 mm | $9.06 tn |
Vanguard | 8.84 mm | $7.76 tn |
JPM JPMorgan Chase & Co. | 7.23 mm | $6.35 tn |
Capital World Investors | 5.13 mm | $4.51 tn |
STT State Street | 4.90 mm | $4.30 tn |
Capital International Investors | 2.92 mm | $2.56 tn |
Dodge & Cox | 2.37 mm | $2.08 tn |
Loomis Sayles & Co L P | 1.22 mm | $1.07 bn |
Putnam Investments | 1.21 mm | $1.06 tn |
MS Morgan Stanley | 1.14 mm | $1.00 tn |
Recent insider trades
Date | Owner | Security | Transaction | Code | Indirect | 10b5-1 | $Price | #Shares | $Value | #Remaining |
---|---|---|---|---|---|---|---|---|---|---|
14 Mar 24 | Murphy Andrew J | Common Stock | Sell | Dispose S | No | Yes | 968.2 | 196 | 189.77 k | 48,306 |
14 Mar 24 | Murphy Andrew J | Common Stock | Sell | Dispose S | No | Yes | 966.3 | 17 | 16.43 k | 48,502 |
14 Mar 24 | Murphy Andrew J | Common Stock | Sell | Dispose S | No | Yes | 965.51 | 78 | 75.31 k | 48,519 |
14 Mar 24 | Murphy Andrew J | Common Stock | Sell | Dispose S | No | Yes | 962.87 | 1 | 962.87 | 48,597 |
14 Mar 24 | Murphy Andrew J | Common Stock | Sell | Dispose S | No | Yes | 961.74 | 47 | 45.20 k | 48,598 |
14 Mar 24 | Murphy Andrew J | Common Stock | Sell | Dispose S | No | Yes | 959.36 | 512 | 491.19 k | 48,645 |
14 Mar 24 | Murphy Andrew J | Common Stock | Sell | Dispose S | No | Yes | 958.34 | 477 | 457.13 k | 49,157 |
14 Mar 24 | Murphy Andrew J | Common Stock | Sell | Dispose S | No | Yes | 957.35 | 730 | 698.87 k | 49,634 |
14 Mar 24 | Murphy Andrew J | Common Stock | Sell | Dispose S | No | Yes | 956.34 | 1,108 | 1.06 mm | 50,364 |
14 Mar 24 | Murphy Andrew J | Common Stock | Sell | Dispose S | No | Yes | 955.54 | 545 | 520.77 k | 51,472 |
News
Behind the Scenes of Regeneron Pharmaceuticals's Latest Options Trends
28 Mar 24
Decoding 12 Analyst Evaluations For Regeneron Pharmaceuticals
26 Mar 24
Truist Securities Maintains Buy on Regeneron Pharmaceuticals, Maintains $1135 Price Target
26 Mar 24
FDA Delays Decision For Regeneron's Inaugural Blood Cancer Therapy, Highlights Trial Concerns
25 Mar 24
Regeneron Pharmaceuticals Unusual Options Activity For March 20
20 Mar 24
Press releases
Revolutionizing Targeted Cancer Treatment and Radiotherapy Manufacturing: Actinium Pharmaceuticals (NYSE: ATNM) Trailblazing Journey
28 Mar 24
Actinium Pharmaceuticals (ATNM): A Prime Buyout Candidate Amidst a Radiopharma Acquisition Wave
26 Mar 24
Regeneron Provides Update on Biologics License Application for Odronextamab
25 Mar 24
Kuehn Law Encourages Investors of Regeneron Pharmaceuticals, Inc. to Contact Law Firm
22 Mar 24
Actinium Pharmaceuticals Inc (NYSE:ATNM) Surges on Analyst Upgrade Amidst Radiopharma Sector Momentum
22 Mar 24